当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2019-07-12 , DOI: 10.1021/acs.jmedchem.9b00454
Christopher Heim 1 , Dimanthi Pliatsika 2 , Farnoush Mousavizadeh 2 , Kerstin Bär 1 , Birte Hernandez Alvarez 1 , Athanassios Giannis 2 , Marcus D Hartmann 1
Affiliation  

Targeted protein degradation via cereblon (CRBN), a substrate receptor of an E3 ubiquitin ligase complex, is an increasingly important strategy in various clinical settings, in which the substrate specificity of CRBN is altered via the binding of small-molecule effectors. To date, such effectors are derived from thalidomide and confer a broad substrate spectrum that is far from being fully characterized. Here, we employed a rational and modular approach to design novel and minimalistic CRBN effectors. In this approach, we took advantage of the binding modes of hydrolyzed metabolites of several thalidomide-derived effectors, which we elucidated via crystallography. These yielded key insights for the optimization of the minimal core binding moiety and its linkage to a chemical moiety that imparts substrate specificity. Based on this scaffold, we present a first active de-novo CRBN effector that is able to degrade the neo-substrate IKZF3 in the cell culture.

中文翻译:


以沙利度胺衍生物天然水解产物为指导的 Cereblon (CRBN) 效应器的从头设计。



通过 cereblon (CRBN)(E3 泛素连接酶复合物的底物受体)进行靶向蛋白质降解是各种临床环境中日益重要的策略,其中 CRBN 的底物特异性通过小分子效应物的结合而改变。迄今为止,此类效应器源自沙利度胺,并具有广泛的底物谱,但尚未完全表征。在这里,我们采用合理和模块化的方法来设计新颖且简约的 CRBN 效应器。在这种方法中,我们利用了几种沙利度胺衍生效应物的水解代谢物的结合模式,并通过晶体学对其进行了阐明。这些为优化最小核心结合部分及其与赋予底物特异性的化学部分的连接提供了关键见解。基于这个支架,我们提出了第一个活性的从头 CRBN 效应器,它能够降解细胞培养物中的新底物 IKZF3。
更新日期:2019-06-28
down
wechat
bug